Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integra Lifesciences ( (IART) ) has shared an announcement.
On May 5, 2026, Integra LifeSciences announced that long-time board chair Stuart Essig has been appointed president and chief executive officer, effective May 1, 2026, succeeding Mojdeh Poul, who departed on April 30, 2026, and that he will also retain his role as chairman. The board emphasized this is a permanent move rather than an interim fix, leveraging Essig’s prior 15-year CEO tenure and recent executive chairman role to accelerate execution, sharpen customer focus and reinforce operating discipline, while a detailed employment package, including equity grants and change-in-control protections, underscores the board’s long-term commitment to his leadership.
The company also named Michael McBreen, previously executive vice president and president of Codman Specialty Surgical, as chief commercial officer in a newly created role designed to centralize the global commercial organization under one leader. His compensation and equity incentives, along with enhanced retirement-related vesting, are structured to align him with Integra’s push to strengthen revenue growth, deepen customer relationships and improve execution across both divisions and its global commercial operations.
The most recent analyst rating on (IART) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Integra Lifesciences stock, see the IART Stock Forecast page.
Spark’s Take on IART Stock
According to Spark, TipRanks’ AI Analyst, IART is a Neutral.
The score is held down primarily by the sharp 2025 deterioration in revenue/profitability and weakened free cash flow. Partially offsetting this are improved leverage, management’s 2026 plan for better cash generation and modest growth, and mixed technicals that show short-term strength but longer-term trend weakness and overbought signals.
To see Spark’s full report on IART stock, click here.
More about Integra Lifesciences
Integra LifeSciences is a global medical technology company focused on neurosurgery, tissue reconstruction and specialized surgical solutions, with a portfolio of differentiated technologies used in life-saving care. The Nasdaq-listed group serves healthcare professionals worldwide and positions itself as a leader in high-precision medical devices and transformative surgical innovations.
Average Trading Volume: 824,077
Technical Sentiment Signal: Strong Sell
Current Market Cap: $828.8M
For detailed information about IART stock, go to TipRanks’ Stock Analysis page.